Literature DB >> 26181455

Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient.

Tatsuo Kanda1, Shingo Nakamoto2, Makoto Arai2, Tatsuo Miyamura2, Shuang Wu2, Keiichi Fujiwara2, Osamu Yokosuka2.   

Abstract

We describe a patient infected with hepatitis C virus (HCV) genotype 1 who failed to respond to interferon with or without ribavirin seven times but who then achieved sustained virological response by the combination of interferon-beta plus ribavirin treatment for 48 weeks. He did not respond to stronger treatment such as prolonged peginterferon plus ribavirin treatment for 87 weeks. It might be rare to treat a patient with interferon 8 times considering the cost and time, since patients failing interferon treatment several times are regarded to be refractory to interferon. It is possible that the difference in biological effects between interferon-alfa and interferon-beta might have resulted in a different outcome in our patient. Interferon-beta plus ribavirin therapy might be one of the treatment options for certain patients chronically infected with HCV who do not respond to standard care treatment.

Entities:  

Keywords:  HCV genotype 1; Hepatitis C; Interferon-beta; Neutralizing antibody; Ribavirin; Sustained virological response

Year:  2013        PMID： 26181455     DOI： 10.1007/s12328-013-0366-1

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN： 1865-7265


  24 in total

1.  Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.

Authors:  S D Der; A Zhou; B R Williams; R H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

2.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Authors: 
Journal:  J Hepatol       Date:  2011-03-01       Impact factor: 25.083

3.  Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1.

Authors:  Keiichi Fujiwara; Osamu Yokosuka; Fumihiko Komine; Mitsuhiko Moriyama; Naoya Kato; Haruhiko Yoshida; Naohide Tanaka; Fumio Imazeki; Yasushi Shiratori; Yasuyuki Arakawa; Masao Omata
Journal:  Liver Int       Date:  2006-06       Impact factor: 5.828

4.  Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1.

Authors:  Tomoo Miyauchi; Tatsuo Kanda; Fumio Imazeki; Rintaro Mikata; Akinobu Tawada; Makoto Arai; Keiichi Fujiwara; Shingo Nakamoto; Shuang Wu; Takeshi Tanaka; Tatsuo Miyamura; Michio Kimura; Yasuo Hirai; Motohide Takashi; Shigeru Mikami; Nobuyuki Sugiura; Yutaka Natsuki; Ryosaku Azemoto; Noriaki Suzuki; Osamu Yokosuka
Journal:  Hepatol Int       Date:  2012-02-10       Impact factor: 6.047

5.  Occurrence of clinical depression during combination therapy with pegylated interferon alpha or natural human interferon beta plus ribavirin.

Authors:  Hideyuki Nomura; Yuugou Miyagi; Hironori Tanimoto; Nobuyuki Yamashita; Seiji Oohashi; Saburo Nishiura
Journal:  Hepatol Res       Date:  2011-12-16       Impact factor: 4.288

6.  Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection.

Authors:  M Milella; G Antonelli; T Santantonio; M Currenti; L Monno; N Mariano; G Angarano; F Dianzani; G Pastore
Journal:  Liver       Date:  1993-06

7.  Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C.

Authors:  F Matsuda; Y Torii; H Enomoto; C Kuga; N Aizawa; Y Iwata; M Saito; H Imanishi; S Shimomura; H Nakamura; H Tanaka; H Iijima; H Tsutsui; Y Tanaka; S Nishiguchi
Journal:  J Viral Hepat       Date:  2012-05-29       Impact factor: 3.728

8.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

Authors:  N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato
Journal:  N Engl J Med       Date:  1996-01-11       Impact factor: 91.245

Review 9.  Treatment predictors of a sustained virologic response in hepatitis B and C.

Authors:  Annika Kau; Johannes Vermehren; Christoph Sarrazin
Journal:  J Hepatol       Date:  2008-07-31       Impact factor: 25.083

10.  An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Authors:  Marc G Ghany; David R Nelson; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2011-09-26       Impact factor: 17.425
View more
  3 in total

Review 1.  Natural interferon-beta treatment for patients with chronic hepatitis C in Japan.

Authors:  Reina Sasaki; Tatsuo Kanda; Shingo Nakamoto; Yuki Haga; Masato Nakamura; Shin Yasui; Xia Jiang; Shuang Wu; Makoto Arai; Osamu Yokosuka
Journal:  World J Hepatol       Date:  2015-05-18

2.  Successful natural interferon-β plus ribavirin therapy in a chronic hepatitis C patient after discontinuation of interferon-α treatment due to arrhythmia and interstitial pneumonia.

Authors:  Akira Sato; Masahiro Yamauchi; Takayuki Yamada; Reiko Kumano; Kayo Adachi; Toshiya Ishii; Mikihito Hayashi; Daisuke Kumon
Journal:  Clin J Gastroenterol       Date:  2014-06-06

3.  Successful Eradication of Hepatitis C Virus by Interferon-Free Regimens in Two Patients with Advanced Liver Fibrosis following Kidney Transplantation.

Authors:  Reina Sasaki; Tatsuo Kanda; Shin Yasui; Yuki Haga; Masato Nakamura; Mutsumi Yamato; Shuang Wu; Shingo Nakamoto; Makoto Arai; Shigeru Mikami; Hideaki Miyauchi; Hisahiro Matsubara; Osamu Yokosuka
Journal:  Case Rep Gastroenterol       Date:  2016-05-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.